Future of pharmaceutical science heavily relies on drug discovery, drug development and research and development productivity. There is a lack of productivity in drug development area.Industries are trying to close this gap for more than a decade by implementing different working models within organization.Drug discovery, drug development and performance and process measuring tools in pharmaceutical science have become very significant and challenging as pharmaceutical industry evolves.Companies have looked in to tools to measure performance to identify the gaps and make research and development area more sustainable. However, drug development and research and development productivity remains un-sustained specifically small scale organizations. Future of pharmaceutical science requires universal tactic that would address the drug development strategies, processes, and investment and organization management. High performance companies can take inclusive deeds to advance and increase research and developmentrevenues.In order to achieve this goal, pharma companies mainly rely on skills, quality and funding. These elements can be strategically managed by contracting research and development activities to third party organization (TPO). This paper describes a robust TPO selection methodology on how to select TPOs thoughtfully that can make organization‟s research and development productivity sustainable. This methodology may also help organizations in filling the productivity gapto remain sustainable.